KIT and gastrointestinal stromal tumor: Similarly, the therapeutic effect of imatinib in GIST requires the immune system and responses to the c-Kit inhibitor dasatinib in c-Kit mutant P815 mastocytomas were dependent on CD8+ T cell-mediated immunity [22, 23].